Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Two experimental vaccine approaches, using mRNA protein delivery and germline targeting, are in the early stages of development.
HTI vaccines could become the backbone of a combination approach for achieving a functional cure.
Molnupiravir, first developed for hepatitis C, might be able to prevent or treat COVID-19 outside of a clinical setting.
Taking meds for four days followed by three days off maintained viral suppression for two years.
Plus, nearly a third of people already taking Truvada for PrEP switched to the new combination pill.
However, all integrase inhibitors were associated with similar weight gain.
13,000 gay and bi Black and Latino men received PrEP care through collaboratives.
I just attended my first CROI (Conference on Retroviruses and Opportunistic Infections). It was also my first virtual conference...
On April 15, full and free access to all virtual session recordings from the HIV and COVID-19 conference will be provided online.
However, even as new cases climbed, deaths declined.
Compared with efavirenz-based regimens, dolutegravir-containing ones resulted in fewer switches and better viral control.
The São Paulo Patient is no longer HIV-free after more than 15 months off treatment, but was it a relapse or reinfection?
Increased HCV testing and treatment for both HIV-positive and HIV-negative gay and bi men could help eliminate hep C.
A 30-year retrospective review of abnormalities among infants born to women using antiretrovirals shows low, consistent levels.
Study results confirm that dolutegravir is a safe and effective treatment for pregnant women with HIV.
A new simulation suggests that by 2030, multimorbidity in people with HIV will rise substantially.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.